NDude Labs invests in nutraceutical ingredients firm Nutriventia

Bengaluru: Healthcare and wellness-focused NDude Labs has invested in Nutriventia, an Indian nutraceutical ingredients company that develops clinically validated, proprietary branded ingredients.

The investment will help Nutriventia strengthen its research and development pipeline, expand its global commercial presence and scale its proprietary ingredient technology platform, the company said in a statement.

Investec served as financial advisor to Nutriventia on the transaction, while Cyril Amarchand Mangaldas and Stratage Law Partners were the legal counsel. PwC served as the due diligence advisor.


“Nutriventia is science-led, innovation-driven and built in India, with the potential to lead its category globally. We’ve been impressed by the team’s ability to combine pharmaceutical-grade science with a sharp understanding of what consumers and brands need,” said Nitin Thakor, managing director, NDude Labs.

Also read | Tata Trusts opposes Chandra’s return; standoff may escalate

Nutriventia’s portfolio includes a low-dose turmeric ingredient for musculoskeletal and joint health, a natural caffeine-based ingredient for mental alertness, among others. The company is also preparing to launch an alpha lipoic acid ingredient.

“We built our proprietary delivery platforms to address pharmaceutical-grade challenges around bioavailability, stability and dosing efficacy,” said Rajat Mittal Shah, co-founder and executive director, Nutriventia.

Nutriventia’s ingredients are currently supplied to formulators and wellness brands across the US, Europe, Australia, South Korea and Japan.

Also read | Modinomics at 76: Birthday cake, candles & numbers

The investment comes as international brands increasingly seek clinically validated and evidence-backed nutraceutical ingredients over commodity products, creating an opportunity for Indian companies with pharmaceutical-grade research capabilities to expand in global markets.